Funding for this research was provided by:
National Parkinson Foundation (PDF-TRG-1722)
Received: 11 September 2018
Accepted: 8 January 2019
First Online: 31 January 2019
Ethics approval and consent to participate
: Both studies referenced in the <i>Tele-monitored tDCS evidence in Parkinson’s disease</i> section corresponding to the authors’ laboratory had the Institutional Review Board of NYU School of Medicine approval. These studies were conducted in accordance with the principles of the Declaration of Helsinki of (2013). All participants were informed about the aims of the study and gave written informed consent.
: All authors reviewed and approved the final submission.
: The projects performed at the Fresco Institute NYU Neurology Department were conducted with a Soterix Mini-CT tDCS devices and custom-made headsets purchased from Soterix Medical. Soterix Medical provided technical support for the equipment. Soterix Medical had no role in study design, data collection, analysis, interpretation, funding or reporting of the results.Doctor Leigh Charvet has provided scientific advice for the study design. Dr. Charvet does not have any patents nor equity in Soterix or any other neuromodulation companies or products discussed.The authors do not have any financial interests in any neuromodulation companies or products discussed.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.